Question

scenario: a group of researchers conduct a randomized, double - blind, placebo - controlled trial on obese, diabetic adults to determine whether the drug, ozempic, is more effective in promoting weight loss than a placebo group and a group receiving another drug (orlistat). after one year, the researchers report that the subjects receiving ozempic lost 5.8 kg (95% confidence interval 3.7 - 8.0; p < 0.0001) more weight than those on placebo and 3.8 kg (95% confidence interval 1.6 - 6.0; p < 0.0001) more than those on orlistat.
in your own words, describe the results of this study.

Explanation:

This is a randomized, double - blind, placebo - controlled trial. The key points are the comparison of weight loss among three groups (Ozempic, placebo, Orlistat). The 95% confidence intervals and p - values ($p\lt0.0001$) indicate statistical significance. The weight loss values (5.8 kg more than placebo, 3.8 kg more than Orlistat) show the magnitude of the effect.

Answer:

In this study, Ozempic was found to be more effective in promoting weight loss among obese, diabetic adults. Subjects on Ozempic lost 5.8 kg more weight than those on placebo (with a 95% confidence interval of 3.7 - 8.0 and a highly significant $p\lt0.0001$) and 3.8 kg more than those on Orlistat (95% confidence interval 1.6 - 6.0 and $p\lt0.0001$). The use of a randomized, double - blind, placebo - controlled design helps to minimize bias, and the statistical significance (low p - values) and confidence intervals give credibility to the conclusion that Ozempic has a real effect on weight loss compared to the other two groups.